脑生物制药公司扩大大麻素产品, 针对医疗疾病的药物研究. Brains Bioceutical expands cannabinoid offerings, targeting pharmaceutical research for medical conditions.

作为天然,符合GMP的大麻素API的领先生产商,BRAINS Bioceutical已扩大其产品范围,包括欧盟GMP认证的CBN,固体晶体THC和CBG的持续开发. Brains Bioceutical, a leading producer of natural, GMP-compliant cannabinoid APIs, has expanded its offerings to include EU-GMP certified CBN, solid crystalline THC, and ongoing development of CBG. 这些产品旨在支持药物研究,以满足诸如神经紊乱、慢性疼痛和炎症等未得到满足的医疗需求。 These products aim to support pharmaceutical research for unmet medical needs like neurological disorders, chronic pain, and inflammation. 该公司的扩张与日益增长的全球大麻素制药市场相吻合,预计到2034年将达到48.7亿美元。 The company's expansion aligns with the growing global cannabinoid pharmaceutical market, projected to reach $4.87 billion by 2034.